Immune Design Corp. | Mutual Funds
Mutual Funds that own Immune Design Corp.
Vanguard Total Stock Market Index Fund
951,025
1.98%
0
0%
07/31/2018
iShares Russell 2000 ETF
760,072
1.58%
-405
0.01%
09/06/2018
Fidelity Select Biotechnology Portfolio
724,123
1.5%
-217,534
0.03%
07/31/2018
Vanguard Extended Market Index Fund
461,740
0.96%
0
0%
07/31/2018
AST Small Cap Value Portfolio
310,600
0.65%
-44,700
0.13%
03/29/2018
iShares Russell 2000 Value ETF
285,989
0.59%
0
0.01%
09/06/2018
Fidelity Advisor Biotechnology Fund
173,035
0.36%
-69,800
0.02%
07/31/2018
Fidelity Spartan Extended Market Index Fund
137,453
0.28%
0
0%
07/31/2018
Nationwide VIT - Multi Manager Small Cap Value Fund
136,800
0.28%
-118,200
0.14%
05/31/2018
Bridgeway Ultra Small Company Market Fund
115,000
0.24%
0
0.1%
12/31/2017
| Address |
1616 Eastlake Avenue East
Seattle Washington 98102
United States
|
|
Employees
|
- |
| Website |
http://www.immunedesign.com |
| Updated |
09/14/2018 |
| Immune Design Corp. is a clinical-stage immunotherapy company focused on cancer with in vivo approaches designed to enable the body's immune system to fight disease. It develops multiple product candidates from its discovery platforms, ZVex and GLAAS. The company was founded by Steven G. |
